Neurotech International Ltd. · ASX:NTI
Neurotech International — Investor Presentation (October 2017)
25 slides from Neurotech International's investor presentation, Oct 4, 2017
Slide 1: Neurotech Investor Presentation (ASX announcement)
Neurotech Investor Presentation For personal use only Perth, Australia & Malta – 4 October 2017 – Neurotech International Limited (ASX: NTI) (“Neurotech” or the “Company”), developer of quality medical solutions in the neuroscience space, is pleased to attach our most recent investor presentation. T
Slide 2: Improving the lives of people with neurological conditions
For personal use only Improving the lives of people with neurological conditions Investor Presentation Neurotech International Limited (ASX: NTI) | October 2017
Slide 3: Neurotech Overview
Neurotech Overview For personal use only ✓ Medical device company, focussed on the development & commercialisation of regulated medical solutions for diagnosis & treatment of neurological disorders ✓ Flagship device Mente Autism provides home-based neurofeedback therapy to children on the autism spe
Slide 4: Capital Structure & Key Shareholders
Capital Structure & Key Shareholders For personal use only Market Capitalisation & Enterprise Value Share Price / Volume History (A$; millions) Units Value ASX Closing Price (A$) Volume (m) 0.60 12.0 Ordinary shares m 88.0 Options m 10.9 0.50 10.0 1 Fully diluted capital m 98.9 0.40 8.0 Share price
Slide 5: Highly Experienced Board
Highly Experienced Board For personal use only Peter O’Connor • Deep experience in global funds management, asset allocation & manager selection advisory Chairman (Non-Exec) • Held senior public company directorships (UK, Canada & Australia) MA, Barrister-at Law • Non-executive director of Northern
Slide 6: Autism Spectrum Disorder (ASD)
Autism Spectrum Disorder (ASD) For personal use only • ASD (or autism) is a lifelong development condition Standard treatments include1 • One in 68 children have some form of ASD Behaviour & • There is no cure, so the goal of every treatment is to: Educational Medication communication Neurofeedback
Slide 7: Market Positioning & Opportunity
Market Positioning & Opportunity For personal use only Medical Neurotechnology Clinical Grade Home Care • Understanding & influencing the brain & • Health care moving toward precision-based nervous system personal care • ‘Next frontier’ in medical science • Particularly for lifestyle disorders & chr
Slide 8: First Target Consumer Market – Europe
First Target Consumer Market – Europe For personal use only United Kingdom Population: 65 million Target market: 32,500 Germany, Austria & Switzerland Populations: 98 million Target market: 49,000 Italy Population: 61 million Prevalence of autism: 1% 3-12 years target segment: 10% of autistic suffer
Slide 9: Mente Platform
Mente Platform For personal use only Clinical grade, medical device suitable for home use Monitor, review & interpret home based therapy data cloud Therapy delivered in comfort of patient’s home Personalise & alter Therapy data sent therapy as securely back to Clinic required Mente Cloud Home ✓ One
Slide 10: How Mente Autism works
How Mente Autism works For personal use only Mente Autism algorithms process the 4 EEG waves & deliver auditory feedback Brainwaves are 3 acquired Auditory feedback consists 5 of different binaural beats tailored on EEG activity Resulting benefits: • Increased relaxation 2 Run the Mente App • Improv
Slide 11: Validation
Validation For personal use only • Neurofeedback stimulation for autism management has been around since the late 1990’s • Over 20 medical papers published on studies of baseload EEG profiles & brain imaging of ASD children, the efficacy of neurofeedback as a treatment form for ASD & other neurologi
Slide 12: 2015 Pilot Study
2015 Pilot Study1 For personal use only • 25 participant study of children diagnosed with autism as undertaken to test the efficacy of a four-channel Mente system • In people with autism, delta waves (normally associated with sleep) are abnormally high while alpha & beta waves (normally associated w
Slide 13: Preliminary US Clinical Trial Outcomes
Preliminary US Clinical Trial Outcomes For personal use only Outstanding preliminary results from US clinical study • Positive changes in autistic children’s neurological function • Many of the children scoring in a normal range after the treatment “…one of the most exciting investigations this year
Slide 14: Certifications
Certifications The Mente Autism device already has European CE Marking, thus enabling sales in Europe, Middle East & For personal use only Australia. The Company will seek to also obtain US FDA clearance for the device. Current Certifications & Registrations FDA Submission Process • Mente Autism & M
Slide 15: Product Bundling
Product Bundling For personal use only Complete Mente Autism Kit Optional Add-ons Pre-configured & locked tablet Remote support RRP €1,700 (ex. VAT)1 end-to-end RRP €1,850 with tablet (ex. VAT) 1 Support Hotline Comprising headband, power supply, earphones, sensors, Quickguide, cloud system & ongoin
Slide 16: New Mente Autism Distribution Partners
New Mente Autism Distribution Partners For personal use only • Marketing & distribution • Exclusive marketing & • Marketing & distribution • Marketing & distribution • Exclusive marketing & partner in Australia distribution partner in Saudi partner in Germany & partner in Greece & Cyprus distributio
Slide 17: Key Achievements & Next Milestones
Key Achievements & Next Milestones For personal use only Achievements Looking Forward… The Company has made substantial achievements in the We are focussed on continuing to let science do the space of less than 12 months: talking, and bringing Mente Autism to the parents and children who need it ✓ N
Slide 18: Contact Details
Contact Details For personal use only Company Investor / Media Relations Wolfgang Storf, Chief Executive Officer Matthew Wright [email protected] [email protected] Neurotech International Ltd NWR Communications Level 14, 191 St Georges Terrace Level 6, 350 Collins St Perth Western
Slide 19: Appendices
For personal use only Appendices
Slide 20: Case Study: German Market Entry Strategy
Case Study: German Market Entry Strategy For personal use only • Distributor agreement signed in April 2017 with VDT Psychologie Medizinvertrieb • Three-step approach to creating structure to develop a successful market in Germany: 1. Appoint distribution partner (done) 2. Build medical professional
Slide 21: Case Study: Germany – First Testimonial
Case Study: Germany – First Testimonial For personal use only “Mert is a five-year-old boy with ASD who has been using Mente Autism for over three months. Within a few weeks of starting the therapy, we noticed several changes in his communication levels, attention & behaviour. Mert’s vocabulary has
Slide 22: Update: Italian Market Entry Strategy
Update: Italian Market Entry Strategy For personal use only • Series of commercial & marketing activities to be organised over the coming months in Italy (Orvieto, Umbria & Corato, Bari), led by distribution partner Promosalute • A group of 15 children are expected to start using Mente Autism in Q4
Slide 23: Mente Autism Testimonials
Mente Autism Testimonials For personal use only 22
Slide 24: Disclaimer
Disclaimer For personal use only This presentation contains forward looking statements that involve risks and uncertainties. These forward looking statements are not guarantees of Neurotech’s future performance and involved a number of risks and uncertainties that may cause actual results to differ
Slide 25: For personal use only
For personal use only www.neurotechinternational.com www.mentetech.com
Neurotech International — Investor Presentation (October 2017) on 6ix